Royalty Report: Drugs, Biotechnology, Medical – Collection: 871

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Medical
  • Supply
  • Pharmaceuticals
  • Wound Care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 871

License Grant
The Licensee entered into an Exclusive Channel Collaboration Agreement with the Licensor that governs a channel collaboration arrangement governing a strategic collaboration for the development and commercialization of genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States.
License Property
Licensor has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression.
Field of Use
Genetically-modified fibroblasts are used to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions.

A fibroblast is a type of biological cell that synthesizes the extracellular matrix and collagen, produces the structural framework (stroma) for animal tissues, and plays a critical role in wound healing. Fibroblasts are the most common cells of connective tissue in animals.

The Field includes the enhanced production and purification of non-genetically modified autologous fibroblasts for all aesthetic and therapeutic indications; the enhanced production and purification of non-genetically modified autologous dermal cells for aesthetic and therapeutic treatment of dermal, vocal cord, and periodontal indications; the development of genetically modified autologous fibroblasts for all aesthetic and therapeutic indications; and the development of genetically modified autologous dermal cells for aesthetic and therapeutic treatment of dermal, vocal cord, and periodontal indications.

IPSCIO Record ID: 2711

License Grant
The Licensor entered into an exclusive License Agreement with the Licensee for the sales and marketing of Orcel product.
License Property
The product is a collagen sponge seeded with allogeneic epidermal and dermal cells. These cells secrete growth factors and cytokines normally found in acute human wounds and are believed to have a beneficial role in promoting tissue repair.

OrCel® is a bilayered cellular matrix in which normal human allogeneic skin cells (epidermal keratinocytes and dermal fibroblasts) are cultured in two separate layers into a Type I bovine collagen sponge.  Donor dermal fibroblasts are cultured on and within the porous sponge side of the collagen matrix while keratinocytes, from the same donor, are cultured on the coated, non-porous side of the collagen matrix.

Field of Use
Field of use relates to the medical industry.

IPSCIO Record ID: 329

License Grant
The Licensor hereby grants to the Licensee a license under the Licensor IP to research, develop, use, import, make, have made, sell, and offer for sale Licensee Products in the Field in the Territory. Such license shall be exclusive (even as to Licensor) with respect to any development, selling, offering for sale or other Commercialization of Licensee Products in the Field in the Territory, and shall be otherwise non-exclusive.  
Licensor grants a non-exclusive, royalty-free license to use and display the Licensor Trademarks, solely in connection with the Commercialization of Licensee Products in the promotional materials, packaging, and labeling.
License Property
The Licensor has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression.

A Bacteriophage is a virus that parasitizes a bacterium by infecting it and reproducing inside it. They are seen as a possible therapy against multi-drug-resistant strains of many bacteria.

Field of Use
Field means genetically modified bacteriophages using synthetic biology, and the production of bacteriophages using synthetic biology, for bacteriophage-containing human therapeutics for use in the treatment of bacterial infections associated with acute and chronic wounds, and the treatment of acute and chronic Pseudomonas aeruginosa lung infections, and the treatment of infections of Clostridium difficile.

Licensee now desires to become exclusive channel collaborator with respect to such technology for the purpose of developing the Bacteriophage Program.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.